Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 737.5 Thousand AUD | -23.38% |
| 2023 | 962.49 Thousand AUD | 18.31% |
| 2022 | 813.56 Thousand AUD | 75.52% |
| 2021 | 463.51 Thousand AUD | -45.67% |
| 2020 | 853.19 Thousand AUD | 104.11% |
| 2019 | 417.99 Thousand AUD | 23.78% |
| 2018 | 337.7 Thousand AUD | -45.49% |
| 2017 | 619.51 Thousand AUD | 78.89% |
| 2016 | 346.31 Thousand AUD | -26.81% |
| 2015 | 473.17 Thousand AUD | -0.31% |
| 2014 | 474.64 Thousand AUD | 21.37% |
| 2013 | 391.07 Thousand AUD | 103.5% |
| 2012 | 192.17 Thousand AUD | -21.34% |
| 2011 | 244.32 Thousand AUD | 74.16% |
| 2010 | 140.28 Thousand AUD | -36.9% |
| 2009 | 222.33 Thousand AUD | -47.56% |
| 2008 | 423.94 Thousand AUD | 160.05% |
| 2007 | 163.02 Thousand AUD | -48.75% |
| 2006 | 318.1 Thousand AUD | 112.24% |
| 2005 | 149.87 Thousand AUD | -2.25% |
| 2004 | 153.33 Thousand AUD | 3.55% |
| 2003 | 148.07 Thousand AUD | 3.63% |
| 2002 | 142.89 Thousand AUD | 28.22% |
| 2001 | 111.44 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 626.16 Thousand AUD | -23.03% |
| 2024 FY | 737.5 Thousand AUD | -23.38% |
| 2024 Q4 | 737.5 Thousand AUD | 0.0% |
| 2024 Q2 | 626.16 Thousand AUD | 0.0% |
| 2024 Q3 | 737.5 Thousand AUD | 17.78% |
| 2023 Q2 | 805.65 Thousand AUD | 0.0% |
| 2023 FY | 962.49 Thousand AUD | 18.31% |
| 2023 Q1 | 805.65 Thousand AUD | -0.97% |
| 2023 Q4 | 813.56 Thousand AUD | -15.47% |
| 2023 Q3 | 962.49 Thousand AUD | 19.47% |
| 2022 FY | 813.56 Thousand AUD | 75.52% |
| 2022 Q2 | 628.65 Thousand AUD | 0.0% |
| 2022 Q3 | 813.56 Thousand AUD | 29.41% |
| 2022 Q1 | 628.65 Thousand AUD | 35.63% |
| 2022 Q4 | 813.56 Thousand AUD | 0.0% |
| 2021 Q3 | 451.21 Thousand AUD | -33.82% |
| 2021 Q4 | 463.51 Thousand AUD | 2.72% |
| 2021 Q1 | 671.13 Thousand AUD | -21.34% |
| 2021 FY | 463.51 Thousand AUD | -45.67% |
| 2021 Q2 | 681.81 Thousand AUD | 1.59% |
| 2020 Q2 | 411.94 Thousand AUD | 0.0% |
| 2020 FY | 853.19 Thousand AUD | 104.11% |
| 2020 Q4 | 853.19 Thousand AUD | 0.0% |
| 2020 Q1 | 411.94 Thousand AUD | -1.45% |
| 2020 Q3 | 853.19 Thousand AUD | 107.11% |
| 2019 FY | 417.99 Thousand AUD | 23.78% |
| 2019 Q1 | 377.23 Thousand AUD | 11.71% |
| 2019 Q2 | 377.23 Thousand AUD | 0.0% |
| 2019 Q4 | 417.99 Thousand AUD | 1.43% |
| 2019 Q3 | 412.08 Thousand AUD | 9.24% |
| 2018 Q3 | 337.7 Thousand AUD | -8.38% |
| 2018 Q4 | 337.7 Thousand AUD | 0.0% |
| 2018 Q2 | 368.59 Thousand AUD | 0.0% |
| 2018 Q1 | 368.59 Thousand AUD | -40.5% |
| 2018 FY | 337.7 Thousand AUD | -45.49% |
| 2017 Q4 | 619.51 Thousand AUD | 0.0% |
| 2017 Q3 | 619.51 Thousand AUD | 81.13% |
| 2017 Q2 | 342.03 Thousand AUD | 0.0% |
| 2017 Q1 | 342.03 Thousand AUD | -1.24% |
| 2017 FY | 619.51 Thousand AUD | 78.89% |
| 2016 Q3 | 346.31 Thousand AUD | 19.69% |
| 2016 FY | 346.31 Thousand AUD | -26.81% |
| 2016 Q2 | 289.33 Thousand AUD | 0.0% |
| 2016 Q1 | 289.33 Thousand AUD | -38.85% |
| 2016 Q4 | 346.31 Thousand AUD | 0.0% |
| 2015 Q2 | 273.07 Thousand AUD | 0.0% |
| 2015 FY | 473.17 Thousand AUD | -0.31% |
| 2015 Q4 | 473.17 Thousand AUD | 0.0% |
| 2015 Q3 | 473.17 Thousand AUD | 73.27% |
| 2015 Q1 | 273.07 Thousand AUD | -42.47% |
| 2014 FY | 474.64 Thousand AUD | 21.37% |
| 2014 Q4 | 474.64 Thousand AUD | 0.0% |
| 2014 Q3 | 474.64 Thousand AUD | 30.97% |
| 2014 Q1 | 362.41 Thousand AUD | -7.33% |
| 2014 Q2 | 362.41 Thousand AUD | 0.0% |
| 2013 Q3 | 391.07 Thousand AUD | 0.0% |
| 2013 Q4 | 391.07 Thousand AUD | 0.0% |
| 2013 FY | 391.07 Thousand AUD | 103.5% |
| 2012 FY | 192.17 Thousand AUD | -21.34% |
| 2012 Q4 | 192.17 Thousand AUD | 0.0% |
| 2011 Q4 | 244.32 Thousand AUD | 0.0% |
| 2011 FY | 244.32 Thousand AUD | 74.16% |
| 2010 FY | 140.28 Thousand AUD | -36.9% |
| 2010 Q4 | 140.28 Thousand AUD | 0.0% |
| 2009 Q4 | 222.33 Thousand AUD | 0.0% |
| 2009 FY | 222.33 Thousand AUD | -47.56% |
| 2008 Q4 | 423.94 Thousand AUD | 0.0% |
| 2008 FY | 423.94 Thousand AUD | 160.05% |
| 2007 Q4 | 163.02 Thousand AUD | 0.0% |
| 2007 FY | 163.02 Thousand AUD | -48.75% |
| 2006 FY | 318.1 Thousand AUD | 112.24% |
| 2006 Q4 | 318.1 Thousand AUD | 0.0% |
| 2005 FY | 149.87 Thousand AUD | -2.25% |
| 2005 Q4 | 149.87 Thousand AUD | 0.0% |
| 2004 FY | 153.33 Thousand AUD | 3.55% |
| 2004 Q4 | 153.33 Thousand AUD | 0.0% |
| 2003 Q4 | 148.07 Thousand AUD | 0.0% |
| 2003 FY | 148.07 Thousand AUD | 3.63% |
| 2002 Q4 | 142.89 Thousand AUD | 0.0% |
| 2002 FY | 142.89 Thousand AUD | 28.22% |
| 2001 FY | 111.44 Thousand AUD | 0.0% |
| 2001 Q4 | 111.44 Thousand AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.616% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 92.303% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.526% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.982% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.75% |
| Mesoblast Limited | 188.44 Million USD | 99.609% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 80.851% |
| Genus plc | 485 Million USD | 99.848% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 87.377% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 70.691% |
| Marizyme, Inc. | 26.67 Million USD | 97.235% |
| ContraFect Corporation | 32.53 Million USD | 97.733% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 80.592% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 62.777% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 80.732% |
| Intellipharmaceutics International Inc. | 12 Million USD | 93.859% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 93.738% |
| MultiCell Technologies, Inc. | 1617.67 USD | -45490.757% |
| Accustem Sciences Inc. | 1.07 Million USD | 31.664% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.047% |
| EV Biologics, Inc. | 2.11 Million USD | 65.131% |
| Q BioMed Inc. | 8.13 Million USD | 90.932% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.111% |
| Neon Bloom, Inc. | 1.22 Million USD | 39.855% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 85.668% |
| Biomind Labs Inc. | 1.49 Million USD | 50.787% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 99.698% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 95.993% |
| Skye Bioscience, Inc. | 14.07 Million USD | 94.759% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 63.31% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -419.025% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 92.209% |
| IMV Inc. | 37.93 Million USD | 98.056% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -266.708% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 87.164% |
| GB Sciences, Inc. | 5.41 Million USD | 86.387% |
| Alpha Cognition Inc. | 7.16 Million USD | 89.706% |
| HST Global, Inc. | 593.59 Thousand USD | -24.245% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Halberd Corporation | 728.71 Thousand USD | -1.206% |
| Enzolytics Inc. | 365.26 Million USD | 99.798% |
| Resverlogix Corp. | 67.39 Million USD | 98.906% |
| Affymax, Inc. | 8.87 Million USD | 91.686% |
| SYBLEU INC | 681.41 Thousand USD | -8.232% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 12.069% |
| argenx SE | 444.95 Million USD | 99.834% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.016% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 56.972% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 93.804% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 79.878% |
| AVAX Technologies, Inc. | 3.99 Million USD | 81.533% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2575.135% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.944% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -209.028% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 80.25% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -8.324% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.379% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 91.844% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1001.926% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 48.565% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.533% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 72.802% |
| BioStem Technologies, Inc. | 15.9 Million USD | 95.363% |
| ONE Bio Corp. | 27.49 Million USD | 97.318% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -58.707% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2588.397% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 41.43% |
| Agentix Corp. | 2.51 Million USD | 70.624% |
| LadRx Corporation | 2.2 Million USD | 66.485% |
| Cell Source, Inc. | 15.8 Million USD | 95.334% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1550.054% |
| Regen BioPharma, Inc. | 5.45 Million USD | 86.487% |
| Regen BioPharma, Inc. | 5.45 Million USD | 86.487% |
| NovAccess Global Inc. | 7.86 Million USD | 90.618% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 97.02% |
| Itoco Inc. | 1.65 Million USD | 55.388% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 64.051% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 87.808% |
| Kadimastem Ltd | 3.5 Million USD | 78.958% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -74.944% |
| CytoDyn Inc. | 127.89 Million USD | 99.423% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1664.415% |
| Mobile Lads Corp. | 1.31 Million USD | 43.852% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 52.916% |
| Qrons Inc. | 1.48 Million USD | 50.46% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 93.323% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 8.814% |
| Rebus Holdings, Inc. | 5.24 Million USD | 85.931% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 87.913% |
| International Stem Cell Corporation | 5.27 Million USD | 86.024% |
| Bioxytran, Inc. | 3.24 Million USD | 77.304% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -17.849% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 84.027% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.201% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.688% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 63.587% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 86.537% |
| Neutra Corp. | 973.52 Thousand USD | 24.244% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.458% |
| PureTech Health plc | 125.58 Million USD | 99.413% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 80.37% |
| IXICO plc | 1.9 Million USD | 61.19% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 96.407% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.286% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Cellectis S.A. | 249.36 Million USD | 99.704% |